Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial
TL;DR Summary
Novavax announced that its COVID-19-Influenza combination and stand-alone influenza vaccines elicited strong immune responses and were well tolerated in a Phase 3 trial involving adults aged 65 and older, with results comparable to existing licensed vaccines, supporting further development and partnership discussions.
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
95%
866 → 42 words
Want the full story? Read the original article
Read on Novavax Investor Relations